- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1918
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Multiple Sclerosis Relapses Following Cessation of Fingolimod ; volume:42 ; number:4 ; day:18 ; month:3 ; year:2022 ; pages:355-364 ; date:4.2022
Clinical drug investigation ; 42, Heft 4 (18.3.2022), 355-364, 4.2022
- Urheber
-
Malpas, Charles B.
Roos, Izanne
Sharmin, Sifat
Buzzard, Katherine
Skibina, Olga
Butzkueven, Helmut
Kappos, Ludwig
Patti, Francesco
Alroughani, Raed
Horakova, Dana
Havrdova, Eva Kubala
Izquierdo, Guillermo
Eichau, Sara
Hodgkinson, Suzanne
Grammond, Pierre
Lechner-Scott, Jeannette
Kalincik, Tomas
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40261-022-01129-7
- URN
-
urn:nbn:de:101:1-2022062508544766332021
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:28 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Malpas, Charles B.
- Roos, Izanne
- Sharmin, Sifat
- Buzzard, Katherine
- Skibina, Olga
- Butzkueven, Helmut
- Kappos, Ludwig
- Patti, Francesco
- Alroughani, Raed
- Horakova, Dana
- Havrdova, Eva Kubala
- Izquierdo, Guillermo
- Eichau, Sara
- Hodgkinson, Suzanne
- Grammond, Pierre
- Lechner-Scott, Jeannette
- Kalincik, Tomas
- SpringerLink (Online service)
Ähnliche Objekte (12)
Multiple sclerosis disease activity and disability following cessation of Fingolimod for pregnancy
Fingolimod Therapy for Multiple Sclerosis
Multiple sclerosis relapses are not associated with exercise
Predictors of severity and outcome of multiple sclerosis relapses
Dramatic recovery of steroid-refractory relapsed multiple sclerosis following Fingolimod discontinuation using selective immune adsorption
Multiple sclerosis, fatigue and sleep disorders: beyond the clinical relapses
Quantitative benefit-risk assessment of methylprednisolone in multiple sclerosis relapses
Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses
Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses
Correlates and trajectories of relapses in relapsing–remitting multiple sclerosis
Fingolimod as a Treatment in Neurologic Disorders Beyond Multiple Sclerosis
Disease Reactivation after Fingolimod Discontinuation in Pregnant Multiple Sclerosis Patients
Multiple sclerosis disease activity and disability following cessation of Fingolimod for pregnancy
Fingolimod Therapy for Multiple Sclerosis
Multiple sclerosis relapses are not associated with exercise
Predictors of severity and outcome of multiple sclerosis relapses
Dramatic recovery of steroid-refractory relapsed multiple sclerosis following Fingolimod discontinuation using selective immune adsorption
Multiple sclerosis, fatigue and sleep disorders: beyond the clinical relapses
Quantitative benefit-risk assessment of methylprednisolone in multiple sclerosis relapses
Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses
Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses
Correlates and trajectories of relapses in relapsing–remitting multiple sclerosis
Fingolimod as a Treatment in Neurologic Disorders Beyond Multiple Sclerosis
Disease Reactivation after Fingolimod Discontinuation in Pregnant Multiple Sclerosis Patients
Multiple sclerosis disease activity and disability following cessation of Fingolimod for pregnancy
Fingolimod Therapy for Multiple Sclerosis
Multiple sclerosis relapses are not associated with exercise
Predictors of severity and outcome of multiple sclerosis relapses
Dramatic recovery of steroid-refractory relapsed multiple sclerosis following Fingolimod discontinuation using selective immune adsorption
Multiple sclerosis, fatigue and sleep disorders: beyond the clinical relapses
Quantitative benefit-risk assessment of methylprednisolone in multiple sclerosis relapses
Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses
Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses
Correlates and trajectories of relapses in relapsing–remitting multiple sclerosis
Fingolimod as a Treatment in Neurologic Disorders Beyond Multiple Sclerosis